Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Significant Increase in Short Interest
by Scott Moore · The Cerbat GemSonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totaling 38,967 shares, an increase of 196.4% from the March 15th total of 13,145 shares. Based on an average daily volume of 41,763 shares, the days-to-cover ratio is presently 0.9 days. Currently, 3.0% of the company’s stock are short sold.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.
Read Our Latest Analysis on Sonoma Pharmaceuticals
Sonoma Pharmaceuticals Stock Performance
NASDAQ SNOA traded down $0.13 during trading hours on Friday, reaching $2.28. 31,213 shares of the company’s stock were exchanged, compared to its average volume of 39,497. The company’s 50-day moving average is $2.61 and its two-hundred day moving average is $3.29. Sonoma Pharmaceuticals has a one year low of $1.98 and a one year high of $6.92. The company has a market capitalization of $3.95 million, a price-to-earnings ratio of -1.12 and a beta of 1.76.
Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.06). Sonoma Pharmaceuticals had a negative return on equity of 42.56% and a negative net margin of 19.04%.The firm had revenue of $4.35 million for the quarter, compared to analyst estimates of $5.47 million. Research analysts predict that Sonoma Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Sonoma Pharmaceuticals
An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. purchased a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned about 0.66% of Sonoma Pharmaceuticals as of its most recent SEC filing. 1.95% of the stock is owned by hedge funds and other institutional investors.
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.
At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.